Kineta, Inc. (KA)
Kineta, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Seattle, WA, US. The stock last traded at $0.57, down 30.77% on the session, giving a market capitalisation of $7.0M. On trailing twelve-month figures it carries a trailing P/E of -0.40, a net margin of 0.0%. Its beta of 0.57 implies it has historically moved less than the broad market.
Kineta, Inc. is a clinical-stage biotechnology firm dedicated to developing immunotherapies, with a focus on oncology, neuroscience, and biodefense applications. The company engages in partnerships with a variety of entities, including private companies, government bodies, and other industry stakeholders. Among its significant strategic collaborators are Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Established in 2007, Kineta, Inc. was previously known as Lecura, Inc. and has its base of operations in Seattle, Washington.
Kineta, Inc. is most often compared with the following Healthcare names: